Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Salix Pharmaceuticals Ltd.

http://www.salix.com

Latest From Salix Pharmaceuticals Ltd.

Lupin Looks To Be First Out Of The Blocks On US Ingrezza, With Zydus Second

ANDA sponsors targeting Neurocrine Biosciences’ Ingrezza (valbenazine) blockbuster are in position to launch – albeit with a 14-year wait that validates the strength of the originator’s IP.

Generic Drugs Deals

Asia Deal Watch: SciClone Obtains Commercial Rights In China To Menarini Breast Cancer Drug

Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.

Deal Watch Business Strategies

Zydus On Acquisitions, $100m Specialty Biz Target, Asacol Competition

Zydus is still on the lookout for deals post the recent acquisition of UK-based LiqMeds group as it sets a $100m sales target from specialty/rare disease products. Meanwhile, US revenues are seen stabilizing with new launches, even as lack of generic Revlimid sales in Q2 led to a 24% drop over the previous quarter.

Sales & Earnings Strategy

Zydus On Acquisitions, $100m Specialty Biz Target, gAsacol Competition

Zydus is still on the look out for deals post the recent acquisition of UK-based LiqMeds group as it sets a $100m sales target from specialty/rare disease products. Meanwhile, US revenues are seen stabilizing with new launches, even as lack of Revlimid sales in Q2 led to a 24% drop over the previous quarter.

Commercial Sales & Earnings
See All

Company Information

  • Other Names / Subsidiaries
    • InKine Pharmaceutical
    • Oceana Therapeutics, LLC
    • Q-Med Scandinavia, Inc.
    • Santarus, Inc.
UsernamePublicRestriction

Register